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Bariatric surgery is currently the most eﬀective and durable therapy for obesity. Roux-en-Y gastric bypass surgery, the most
commonly performed procedure worldwide, causes substantial weight loss and improvement in several comorbidities associated
with obesity, especially type 2 diabetes. Several mechanisms are proposed to explain the improvement in glucose metabolism after
RYGB surgery: the caloric restriction and weight loss per se, the improvement in insulin resistance and beta cell function, and
ﬁnally the alterations in the various gastrointestinal hormones and adipokines that have been shown to play an important role in
glucose homeostasis. However, the timing, exact changes of these hormones, and the relative importance of these changes in the
metabolic improvement postbariatric surgery remain to be further clariﬁed. This paper reviews the various changes post-RYGB in
adipokines and gut peptides in subjects with T2D.
1.Introduction
The epidemic of obesity continues to increase, followed in
close parallel by T2D, and the World Health Organization
estimates show that by 2015, around 2.3 billion adults will
be overweight and greater than 700 million will be obese
[1]. Recommendations to achieve weight loss include pri-
marilylifestylemeasuressuchasdietarytherapyandexercise,
limited pharmacological treatment, and bariatric surgery.
Bariatric surgery has proven so far to be the most eﬀective
and durable treatment option for both the excess weight
and the related comorbidities [2, 3]. Strong evidence has
revealed that in addition to inducing major weight loss,
bariatric surgery further ameliorates diabetes, hypertension,
and dyslipidemia [4]. Of those with T2D, 78% had complete
resolution following surgery and diabetes improved or
resolved in 86.6% of patients. The greatest eﬀect on weight
loss and diabetes resolution was seen in patients undergoing
biliopancreatic diversion/duodenal switch followed by gas-
tric bypass and then banding procedures [5].
Amongthevarioustechniquesinbariatricsurgery,RYGB
is the most common bariatric surgery performed worldwide
and is considered by many surgeons as the “gold standard”
procedure [6]. The RYGB operation was developed in the
1960’s following observations of weight loss after gastric
resection for peptic ulcer disease. Surgeons worked on
multiple alterations of the operation and deduced that for
eﬀective weight reduction, the stomach size needs to be
reduced to less than 50mLs. This small part of the stomach
that remains in continuity with the digestive tract is referred
to as the gastric pouch, whereas the majority of the stomach
and the duodenum are excluded and are no longer in direct
contact with food. The gastric pouch is then reattached to
the small intestines using either staples or sutures, and this
connection is referred to as the stoma. The preferred way
to connect the pouch to the small intestine is via a Roux-y-
conﬁguration as shown in Figure 1. In the RYGB, the food
goes across the pouch into the “alimentary limb”, whereas
the biliary and pancreatic juices ﬂow a distance away from2 ISRN Endocrinology
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Figure 1: Roux-en-Y gastric bypass. P: gastric pouch. AL: alimen-
tary limb. BPL: biliopancreatic limb.
the pouch to form what is referred to as the “biliopancreatic
limb” to minimize the harmful eﬀects of “bile reﬂux” [7].
Several studies have demonstrated the dramatic eﬀect of
RYGB on T2D occurring as early as 6 days postoperatively
long before major weight loss has occurred [8]. Elucidating
the mechanisms of improvement of diabetes after RYGB may
lead to a better understanding of the pathophysiology of
T2D and guide the search for novel therapies. Hypothesis
linking the early and rapid metabolic improvement to
bariatricsurgeryhavefocusedonhormonalchanges,namely,
adipokines and gut peptides. Therefore, the purpose of this
paperistocriticallyreviewtherecentdataandclinicalstudies
addressing the changes in gut-related peptides and other
hormones after RYGB surgery and the resulting alterations
in metabolic proﬁle.
2.LiteratureSearch
A Pubmed search through the English Literature was con-
ducted from 1979 to 2010 using various combinations
of the following key words: “adiponectin”, “amylin”, “bar-
iatric surgery”, “gastric bypass”, “gastrointestinal hormones”,
“GLP-1”, “ghrelin”, “gut hormones”, “insulin”, “leptin”,
“metabolic surgery”, “obesity”, “oxyntomodulin”, “peptide
YY” (PYY), and “Roux-en-Y gastric bypass” (RYGB). Only
longitudinal and cross-sectional studies assessing hormonal
changesafterRYGBsurgeryinobesityanddiabetesfromyear
2000 to 2010 were identiﬁed and included due to paucity of
studies addressing this issue before year 2000.
3. Mechanisms of Improvement of
Diabetesafter RYGBSurgery
Weight loss per se and the decrease in fat mass induced by
bariatric surgery reduce insulin resistance through the direct
and indirect eﬀects of adipocytokines and through the fall in
lipid content in both liver and muscle. Furthermore, caloric
restriction imposed by bariatric surgery allows the beta-cells
to rest and they are thus minimally challenged. A signiﬁcant
improvement in glucose homeostasis that is independent
of weight loss can be achieved by following a very low-
caloric diet [9, 10]. One study by Henry et al. showed that
a 330cal/day diet resulted in reduction in fasting plasma
glucosefrom297mg/dLto138mg/dLover40dayswith87%
of this drop occurring in the ﬁrst 10 days [10]. However,
the eﬀects of weight reduction and caloric restriction alone
do not account for the dramatic and sustained eﬀects of
bariatric surgery on diabetes, long after negative caloric
balance had ceased. Two hypotheses have been proposed to
explain how bariatric surgery improves diabetes early on.
(1) Hind gut hypothesis: this hypothesis holds that
diabetes control results from the rapid delivery of
nutrients to the lower intestine overstimulating the
L cells to release gut hormones such as GLP-1,
peptide YY, and oxyntomodulin. These hormones
exert anorectic and insulinotropic eﬀects to various
e x t e n t st h u si m p r o v i n gg l u c o s eh o m e o s t a s i s[ 11, 12].
(2) Foregut hypothesis: in normal conditions, the pas-
sage of nutrients along the proximal bowel stimulates
the production of an unidentiﬁed factor with anti-
incretin properties responsible for insulin resistance
and abnormal glycemic control. Thus, the exclusion
of the proximal intestine would reduce the produc-
tion of anti-incretins and would therefore increase
insulin secretion and action and improve diabetes
[12–14].
Rubino et al. supported the foregut hypothesis as an
explanation for the improvement in glucose homeostasis
after RYGB surgery. They showed that excluding the pro-
ximal intestine in Goto-Kakizaki (GK) diabetic rats that have
undergone gastrojejunostomy ameliorated their diabetes
compared to rats with an intact duodenal passage. Con-
versely, in rats that had undergone duodenal-jejunal bypass,
restoration of their duodenal passage reestablished their
impaired glucose tolerance [15] .Ar e c e n ts t u d yb yK n o p
suggested a possible role for glucagon or gut-derived gluca-
gonotropic signaling as diabetogenic signal of the foregut
hypothesis [14].
Since RYGB signiﬁcantly changes the anatomy of the
gastrointestinal tract, alteration in the secretion of several
gutpeptidesensues.Thesehormonesareinvolvedinappetite
regulation and energy balance and have been implicated in
glucose homeostasis as well. In the next section follows a
detailed review of individual peptides and hormones.
4. Gut Hormones
4.1. Ghrelin. Ghrelin is a 28 aminoacid peptide secreted
predominantly by the X/A-like enteroendocrine cells of the
fundus of the stomach [16]. Plasma ghrelin levels rise
nearly twofold before a meal and fall within one hour after
eating [17]. It is the only known circulating orexigen.
Ghrelin circulates in two diﬀerent forms: acylated ghrelin
and desacylated ghrelin [18]. Acyl-ghrelin accounts for lessISRN Endocrinology 3
than 10% of the total circulating ghrelin. It binds to GHSR1a
r e c e p t o ra n ds t i m u l a t e sf o o di n t a k ea sw e l la sG Hs e c r e t i o n
[19]. Des-acyl ghrelin, the major circulating form of ghrelin,
does not bind to GHSR1a receptor but it is not biologically
inactive.However,ithasbeenshowntocounteracttheeﬀects
of acyl-ghrelin on insulin secretion and glucose metabolism
in humans [20] and reduce food intake in mice [21].
How does ghrelin contribute to diabetes resolution after
RYGB surgery?
Ghrelin has been shown to increase levels of GH [22],
cortisol, and epinephrine [23], three counter regulatory hor-
mones that oppose insulin action. It decreases as well secre-
tion of the insulin sensitizing hormone adiponectin [24].
In addition, ghrelin suppresses intracellular insulin signaling
in cultured hepatocytes [25] impairing hepatic insulin sensi-
tivity. Furthermore, ghrelin could inﬂuence insulin secretion
by a direct eﬀect on the pancreas as the ghrelin receptor
GHSR1-a is expressed in various tissues including the pan-
creatic islets [26, 27]. Exogenous ghrelin administration de-
creases insulin secretion in both human and animal studies
[28, 29]. Some studies report improved glucose disposal by
muscle under ghrelin; however, the eﬀect of ghrelin on
the liver is that of insulin insensitivity so that the overall
riding eﬀect is that of an increase in plasma glucose [30,
31]. Therefore suppression of ghrelin after RYGB surgery is
associated with improved glucose homeostasis.
Studies reporting changes in ghrelin levels after RYGB
surgery have shown conﬂicting results (see Table 1). Ghrelin
levels have been reported to decrease as early as during the
intraoperative period following division of the stomach [32]
or later [33–38]. Other studies have reported no change in
ghrelin levels after RYGB surgery [34, 39–41].
4.2. Glucagonlike Peptide-1 (GLP-1). Glucagonlike peptide-
1 is a 30 aminoacid peptide secreted by the L cells of the
distal ileum and colon in response to ingested nutrients.
It enhances glucose-dependent insulin release and improves
beta cell function [42, 43]. Furthermore, it inhibits glucagon
secretion, delays gastric emptying and indirectly decreases
food intake [44]. Circulating GLP-1 has a short half-life
of less than 2 minutes principally due to its inactivation
by the plasma enzyme dipeptidyl peptidase-IV (DPP-IV)
[45].ChronicsubcutaneousGLP-1administrationimproved
glycemic control and decreased body weight in type 2
diabetic patients [46]. In fact, GLP-1 R agonists, resistant
to DPPIV inactivation, have been successfully used in the
treatment of diabetes. Similarly, direct DPPIV inhibitors
also improve glycemic control in T2D, although to a lesser
extent, likely because endogenous GLP-1 levels are low in
diabetes.Therefore,GLP-1retainsitsinsulinotropicproperty
in diabetic subjects, but its circulating levels are decreased
[47, 48].
In theory, GLP-1 should increase after RYGB due to the
rapid nutrient delivery to the ileum where most of the L
cells are located. Most data obtained regarding changes in
GLP-1 after RYGB surgery have shown an increase [49–58],
supportive of this theory, except for one study which showed
adecreaseinbothcontrolsandsubjects[59].Fewothershave
shown no change [41, 60, 61]. A summary of the studies is
presented in Table 2.
4.3. Glucose-Dependent Insulinotropic Polypeptide (GIP).
Glucose-dependent insulinotropic peptide formerly known
as gastric inhibitory polypeptide is a 42 aminoacid peptide
that is secreted by the K cells of the duodenum and jejunum
in response to ingested nutrients. It enhances glucose-
dependent insulin secretion [62]a n dp r o m o t e sb e t ac e l l
proliferation [63]. Higher levels of basal GIP as well as an
increasedearlyphasepostprandialGIPresponsewereseenin
obese subjects compared to lean individuals [48]. In subjects
with T2D, the overall eﬀect of GIP seems to be in favor of
hyperglycemia. In a recent study by Chia et al., exogenous
administration of GIP raised glucose levels in type 2 diabetic
patients in both early and late postprandial phases [64].
One mechanism is the impaired insulinotropic action of
GIP which has been observed particularly during the late
phase of insulin secretion [47]. This could be explained
by a defective expression of GIP receptors as observed in
Zucker diabetic fatty rats [65]. Secondly, although GIP is an
insulinotropic hormone, an elevation of glucagon secretion
with GIP infusion was observed in the early postprandial
phase counteracting insulin glucose lowering eﬀect. Thirdly,
exogenous administration of GIP, as reported by Chia et
al., worsened hyperglycemia in the late postprandial phase
evoking a potential suppressive eﬀect of GIP on GLP-
1[ 64]. Furthermore, GIP may be directly implicated in
fat metabolism and development of obesity by inﬂuencing
insulin sensitivity of adipocytes. GIP promotes deposition
of fat in adipose tissues and inhibits lipolysis [66, 67]. Mice
lacking GIP receptors [68]o rKc e l l s[ 69]were protected
from obesity when fed a high-fat diet, and young prediabetic
ob/ob mice treated with (Pro3)G I Pas p e c i ﬁ ca n ds t a b l eG I P
receptor antagonist prevented the development of diabetes
and related metabolic abnormalities in these rodents [70]
Therefore, GIP receptor antagonists, by opposing GIP’s
anabolic action on adipose tissue, could represent a new
treatment modality for obesity [71].
Since GIP is secreted by the proximal gut, bypassing the
duodenum and part of the jejunum in the RYGB surgery is
expectedtoresultinadecreaseinGIPsecretionandtherefore
a more favorable glycemic milieu. Studies involving GIP
and RYGB surgery have shown inconsistent results. Reduced
levels postoperatively have been reported in some studies
[60, 61] while others reported no change or an increase in
GIP levels after surgery as shown in Table 3 [49, 50, 72, 73].
4.4. Oxyntomodulin (OXM). Oxyntomodulin is a 37 amino-
acid peptide derived from proglucagon cosecreted with
GLP-1 and PYY from the L cells of the distal gut in
response to ingested nutrients [74]. Central and peripheral
administration of OXM has been observed to reduce food
intake in rats [75]. Infusion of OXM in humans prolonged
gastric emptying, reduced pancreatic exocrine secretion, and
decreased food intake [76, 77]. Furthermore, subcutaneous
administrationofOXMdecreasedbodyweightinoverweight
and obese individuals [78]. However, the eﬀect of exogenous4 ISRN Endocrinology
Table 1: Ghrelin and RYGB surgery.
Author/year Type of study Subjects Preop BMI % weight loss F/U time Change in hormone
Geloneze et al.
2003 [33]
Prospective
controlled
28 RYGB
surgery
14 T2D
14 NGT
lean group
56.3 ±10.2
24.2 ±1.5
%E W L
67.4 ±13.4 1y
Lower ghrelin levels in obese
compared to lean presurgery;
No diﬀerence in fasting ghrelin in
T2D and NGT before surgery;
Decrease in fasting ghrelin in both
T2D and NGT after surgery.
Lin et al. 2004 [32] Prospective
controlled
34 RYGB
4V B G
4A R S
4 lean ARS
47.0 ±0.7
43.7 ±2.5
40.0 ±2.0
23.8 ±0.9
NA 30min
postop
Ghrelin higher in lean ARS
compared to pre-RYGB;
Decrease in ghrelin levels
post-RYGB to levels lower that
lean ARS;
Fr¨ uhbeck et al.
2004 [37]
Prospective
controlled
8R Y G B
8A G B
8C o n v
6T o t a l
gastrectomy
44.2 ±2.6
44.8 ±1.6
43.7 ±1.5
29.9+1 .1
NA 6mo
At 6mo, lower fasting ghrelin in
RYGB and gastrectomy groups
compared to AGB and conv group;
No diﬀerences in fasting ghrelin at
6mos between RYGB group and
gastrectomy group.
Couce et al., 2006
[34]
Prospective
controlled
49 obese (30 F)
RYGB
19 obese
(9 F) other
GI surgeries
50 ±5.3
29.8 ±3.1 NA
2hr
10d
6mo
Decrease in fasting ghrelin at 2hr
in both groups compared to
preop;
Decrease in fasting ghrelin 10d
postop in only RYGB group
compared to preop;
At 6mo, no change in ghrelin
levels in both groups compared to
preoperative levels.
Mor´ ınigo et al.
2008 [35]
Prospective
controlled
25 non diabetics
RYGB (6 F)
6n o n o b e s e( 2
F)
10 severely
obese
T 2 D( 5F )R Y G B
48.8 ±1.2
49.2 ±2.0 43.0 ±2.36 a n d 5 2 w k
Decrease in fasting plasma ghrelin
at 6wk postop;
At 52wk, plasma ghrelin returned
to baseline levels.
Karamanakos et al.
2008 [40]
Prospective
controlled
16 RYGB (12 F,
2T 2 D )
16 LSG (15 F, 1
IGT)
46.6 ±3.7
45.1 ±3.6
%E W L a
60.5 ±10.7
69.7 ±14.6
1, 3, 6 and
12mo
No signiﬁcant change in fasting
ghrelin RYGB group;
Signiﬁcant decrease in LSG.
Oliv´ an et al. 2009
[39]
Prospective
controlled
21 T2D
10 RYGB
11 diet
9o b e s e
nondiabetics
47.4 ±10.6
42.8 ±3.8
45.5 ±7.1
NA 10Kg weight
loss
No change in fasting ghrelin after
RYGB
Fr¨ uhbeck et al.
2004 [38]
Retrospective
controlled
6R Y G B
7A G B
3B P D
42.6 ±1.6
45.6 ±1.8
60.5 ±7.3
50.1 ±4.4
42.2 ±3.1
54.2 ±4.3
6.1 ±0.4mo
7.0 ±0.6mo
4.4 ±0.8mo
Signiﬁcant decrease in fasting
ghrelin in RYGB group compared
to the other 2 groups
Foschi et al. 2008
[36]
Retrospective
controlled
10 RYGB (9 F)
12 VBG (11 F)
44.1 ±1.8
42.9 ±1.6 20
20%
reduction in
BMI
(= 131 ± 6d
for RYGB)
(119 ± 4.2f o r
VBG)
Basal ghrelin plasma levels
reduced after RYGBP but
increased after VBG
Rodieux et al. 2008
[41]
Cross-
sectional
controlled
8R Y G B
6G B
8w e i g h t
matched
44.9 ±1.8
41.1 ±0.5
29.2 ±0.8
47.8 ±3.3
32.4 ±2.0
9t o4 8m o
25 to 85mo
No change in fasting ghrelin
Maximal PP suppression of
ghrelin greatest in RYGB group
Abbreviations: ABG: adjustable gastric banding, ARS: anti-reﬂux surgery, Conv: conventional weight loss, GB: gastric banding, GI: gastrointestinal, IGT:
impaired glucose tolerance, NA: data not available, LSG: laparoscopic sleeve gastrectomy, Postop: postoperatively, RYGB: Roux-en-y gastric bypass, T2D: type
2 diabetes, VBG: vertical banded gastroplasty.
a%E W L :e x c e s sw e i g h tl o s s= [(operative weight − follow-up weight)/operative excess weight] × 100.ISRN Endocrinology 5
Table 2: GLP-1 and RYGB surgery.
Author/year Type of study Subjects Preop BMI % weight loss F/U time Change in hormone
Mor´ ınigo et al.
2006 [51]
Prospective
controlled
9( 7F )R Y G B
non diabetic
6o b e s e( 4F )
47.4 ±6.1
43.6 ±7.9 NA 6wk
Greater increase in active GLP-1
postmeal in RYGB group postop
compared to weight-matched
obese
Laferr` ere et al.
2007 [50]
Prospective
controlled
8F T2DM RYGB
7 non diabetic
obese
43.6 ±6.8
37.1 ±11.6 NA 1mo
Fasting- and glucose-stimulated
GLP-1 similar in S and C
1 month after RYGB, increase in
GLP-1 (total and active) in
response to oral glucose
Reinehr et al. 2007
[59]
Prospective
controlled
30 obese (26 F)
19 RYGB
11 GB
45.7 ±7.4 50% 2 y Decrease in fasting GLP-1 in
both groups
Le Roux et al. 2007
[56]
Double-blind
randomized
prospective
controlled
7R Y G B
6A G B
44.5 ±2.9
41.9 ±7.5 NA 9.5 ±1.5mo
17 ±1.4mo
Early (2d) and increased
responses of PP GLP-1 in RYGB
group only
Laferr` ere et al.
2008 [49]
Prospective
controlled
9FT 2 DR Y G B
10 F T2D diet
induced weight
loss
43.3 ±6.2
43.3 ±3.6 NA
1mo
10Kg weight
loss
Increase in total GLP-1 after oral
glucose and GLP-1 AUC after
RYGB but not after diet
Peterli et al. 2009
[54]
Randomized
prospective
controlled
13 RYGB
14 LSG
47 ±6.4
45.7 ±6.7 NA 1wk and 3mo Increased PP GLP-1 RYGB > LSG
Clements et al.
2004 [61]
Prospective
uncontrolled
20 obese (15 F)
with T2D 52.7 ±8.8N A 2, 6, and 12wk
postop
No change in fasting GLP-1 at
any time point
Rubino et al. 2004
[60]
Prospective
uncontrolled
S: 10 (9 F, 6
T2D) obese
RYGB
46.2 NA 3wk No change in fasting GLP-1 in
postop
Borg et al. 2006
[57]
Prospective
uncontrolled 6 RYGB 48.3 NA 1, 3, 6mo
postop
PP GLP-1 AUC increased at 6mo
postop
Mor´ ınigo et al.
2006 [52]
Prospective
uncontrolled
34 RYGB
( 2 3F ,1 2N G T ,
12 IGT, 10 T2D)
49.1 ±1.0
NGT:
34.5 ±1.4
IGT: 29.2 ±1.9
DM: 32.0 ±2.4
6wk12mo
I n c r e a s ei nP PG L P - 1A U C
response in IGT and NGT at
6wk
I n c r e a s ei nP PG L P - 1A U C
response in all 3 groups at 12mo
De Carvalho et al.
2009 [53]
Prospective
uncontrolled
11 NGT (9 F)
RYGB
8A G M( 4
T2DM, 4 IGT)
(7 F) RYGB
46.1 ±2.27
46.5 ±2.04%
39.3 ±2.24
36.4 ±2.6
T1: First
evaluation
T2: presurgery
T3: 9mo after
surgery
Increase in GLP-1 levels after
OGTT in both groups at T3
Kashyap et al.,
2010 [73]
Prospective
uncontrolled
16 (7 F) T2D
9R Y G B
7G R
47 ±9 10% 4wk
No change in fasting GLP-1 in
both groups
I n c r e a s ei nP PG L P - 1r e s p o n s ei n
RYGB group only
Le Roux et al. 2006
[55]
Cross-
sectional
controlled
6R Y G B
6GB
12 obese
15 lean
49.8
46.1
47.1
23.8
NA 6 to 36mo
Higher postprandial GLP-1
response in RYGB group
compared to fasting levels and to
other groups
Korner et al. 2007
[58]
Cross-
sectional
controlled
13 F non
diabetic RYGB
10 F BND
13 F OW
31.3 ±1.3
36.1 ±1.7
36.1 ±2.2
35.6 ±2.4
24.6 ±2.3
24.6 ±2mo
postop
Fasting GLP-1 similar in all
groups
At 30min postmeal, GLP-1
higher in RYGB group compared
to BND and OW
GLP-1 AUC at 180min greater in
RYBG group compared to other
groups6 ISRN Endocrinology
Table 2: Continued.
Author/year Type of study Subjects Preop BMI % weight loss F/U time Change in hormone
Rodieux et al. 2008
[41]
Cross-
sectional
controlled
8R Y G B
6GB
8w e i g h t
matched
44.9 ±1.8
41.1 ±0.5
29.2 ±0.8
47.8 ±3.3
32.4 ±2.0
9t o4 8m o
(RYGB)
25 to 85mo
(GB)
No diﬀerence in fasting GLP-1
between 3 groups;
Exaggerated GLP-1 PP
Response in RYGB.
Abbreviations: AUC: area under the curve, AGM: abnormal glucose metabolism, BND: adjustable gastric banding, GR: gastric restrictive, IGT: impaired
glucose tolerance, LSG: laparoscopic sleeve gastrectomy, NA: data not available, NGT: normal glucose tolerance, OGTT: oral glucose tolerance test,O W :
overweight, Postop: postopertaively, PP: postprandial, RYGB: Roux-en-y gastricbBypass, T2D: type 2 diabetes.
Table 3: GIP and RYGB surgery.
Author/year Type of study Subjects Preop BMI % weight loss F/U time Change in hormone
Laferr` ere et al.
2007 [50]
Prospective
controlled
8FT 2 DR Y G B
7 nondiabetic
obese
43.6 ±6.8
37.1 ±11.6 NA 1mo
Fasting- and glucose-stimulated
GIP similar in S and C
1 month after RYGB, increase in
GIP in response to oral glucose.
Laferr` ere et al.
2008 [49]
Prospective
controlled
9FT 2 DR Y G B
10 F T2D
diet-induced
weight loss
43.3 ±6.2
43.3 ±3.6 NA
1mo
10Kg weight
loss
No change in fasting GIP in both
groups.
Increase in peak GIP after OGTT
in RYGB group only.
Rubino et al., 2004
[60]
Prospective
uncontrolled
10 (9 F, 6 T2D)
obese RYGB 46.2 NA 3wk
Baseline GIP higher in diabetics
compared to nondiabetics.
Decrease in fasting GIP in
diabetics only.
Clements et al.
2004 [61]
Prospective
uncontrolled
20 obese (15 F)
with T2D 52.7 ±8.8N A2, 6 and
12wk postop
Decrease in fasting GIP at 6 and
12wk.
Whitson et al. 2007
[72]
Prospective
uncontrolled
10 (9 F, 5 T2D)
RYGB 50 ±6N A 6 m o No change in GIP postop
(nonfasting).
Kashyap et al. 2010
[73]
Prospective
uncontrolled
16 (7 females)
T2D
9R Y G B
7G R
47 ±9 10% 4wk No change in fasting or PP GIP in
both groups.
Korner et al. 2007
[58]
Cross-
sectional
controlled
13 F RYGB
10 F BND
13 F overweight
31.3 ±1.3
36.1 ±1.7
36.1 ±2.2
35.6 ±2.4
24.6 ±2.3
24.6 ±2mo
postop Blunted PP GIP peak after RYGB
Abbreviations: BND: adjustable gastric banding, GR: gastric restrictive, NA: data not available, OGTT: oral glucose tolerance test, Postop: postoperatively, PP:
postprandial, RYGB: Roux-en-y gastric bypass, T2D: type 2 diabetes.
OXM on glycemic control in diabetic subjects has not been
assessed.
Similar to GLP-1 and PYY, bariatric surgeries that
accelerate the delivery of enteral nutrients to distal intestine
should result in an increase in OXM levels. One recent study
by Laferr` ere et al. observed a marked increase in OXM levels
1 month after RYGB surgery in morbidly obese women with
T2D [79].
4.5. Peptide YY(PYY). Peptide YY is a 36 aminoacid peptide,
member of the pancreatic polypeptide family, secreted by
the L cells of the terminal ileum and colon postprandially
in response to food [80]. It circulates in two endogenous
forms: PYY(1–36) and PYY(3–36) with the latter consti-
tuting the main circulating form [81]. PYY(3–36) binds to
the neuropeptide Y subtype 2 receptor (NPY2) in the
hypothalamus and decreases appetite and food intake as
seen in rodents and humans when infused peripherally
[82, 83]. Chronic intravenous administration of PYY in
obese rodents resulted in a dose-dependent weight reduction
[84]. PYY(3–36) infusion also decreased ghrelin levels [83].
Furthermore, when a selective NPY2 polyethylene glycol-
conjugated (PEGylated) peptide agonist was infused in
diet-induced obese (DIO) mice, improvements in glucose
disposal as well as in plasma insulin and glucose levels were
observed [85].
Similar to GLP-1, PYY levels are low in obesity [86, 87]
and at least a blunted response to a meal has been described
in T2D. Levels increase after RYGB surgery in both obese and
diabetic subjects and may account for the added beneﬁcial
satiety and metabolic eﬀects of this procedure [35, 39, 40, 51,
56,57,59,88].AsummaryofthestudiesispresentedinTable
S1 (see Table S1 in supplementary materials available online
at doi:10.5402/2012/504756).
4.6. Amylin. Amylin is a 37 aminoacid peptide cosecreted
with insulin from pancreatic beta cells. It plays a role in
glucose homeostasis by slowing gastric emptying [89],
suppressing glucagon postprandial secretion and decreasing
food intake [90, 91]. Furthermore, amylin has been found toISRN Endocrinology 7
have a synergistic eﬀect with leptin on eating, body weight,
and body adiposity and a synergistic eﬀect with PYY in con-
trolling food intake [92, 93]. A state of amylin deﬁciency has
been observed in diabetes as seen in rats with streptozotocin-
induced B-cell damage and in the spontaneously diabetic
BB Wistar rats [94]a sw e l la si nh u m a n s[ 95]. Therefore,
as with insulin, secretion of amylin requires the presence of
functioning beta cells. In parallel to the insulin levels, fasting
plasma amylin levels are increased in patients with early type
T2D and obesity, suggestive of a state of amylin resistance
[96]. Consequently, high amylin levels are expected in obese
subjectswithT2D,andareductionintheirlevelswithweight
loss should be observed in theory.
StudiessupportivehaveshownthatmaleSpragueDawley
obese rats had a signiﬁcant reduction in plasma amylin levels
after RYGB surgery [97]. Similarly, a decrease in amylin
levels was reported by Bose et al. in morbidly obese diabetic
women at one month after RYGB surgery [98]. Kashyap et
al., however, reported no change in fasting and postprandial
amylin levels in obese type 2 diabetic subjects up to 4 weeks
after RYGB surgery as shown in Table S2 [73].
4.7. Insulin. Insulin is a 53 aminoacid hormone secreted by
the beta cells of the pancreas. It increases uptake of glucose
into target cells, promotes formation of glycogen, and de-
creases gluconeogenesis. A reduction in circulating insulin
levels has been observed after RYGB surgery with improved
insulin sensitivity as measured by homeostasis model assess-
ment of insulin resistance (HOMA-IR). Improvement in
insulin resistance has been reported as early as 6 days after
RYGB surgery before any major weight loss has occurred [8].
The mechanism behind the early improvement in insulin
resistance remains unclear. Caloric restriction early on after
RYGB surgery can decrease hepatic glucose production
[99] and reduce skeletal muscle insulin resistance [100]. In
addition, the changes in adipocytokine and gut hormones
proﬁlethatensuefollowingRYGBsurgeryactsimultaneously
to variable extents to improve insulin sensitivity.
5.Adipokines
Adipokines are bioactive peptides secreted from adipocytes
thathavemultipleeﬀectsonmetabolismwithcurrentlymore
than 50 adipokines identiﬁed [101]. The eﬀect of these
adipocyte-secreted factors on glucose homeostasis has been
better elucidated in recent years. Both leptin, one of the
ﬁrst adipokines discovered to inﬂuence body fat mass and
adiponectin, the most abundant adipocyte-derived protein,
have been extensively studied in the regulation of carbohy-
drate and fat metabolism. Furthermore, favorable changes
in their circulating levels after bariatric surgery have been
assessed in various studies as described in the following
paragraph.Otheradipokinessuchasresistin,visfatin,vaspin,
omentin, serum-retinol-binding protein (RBP)-4, chemerin,
interleukin (IL)-6, plasminogen activator inhibitor (PAI-
1), tumor necrosis factor (TNF), alpha, serum amyloid A,
and angiotensinogen may have a role in obesity and T2D.
However, data on changes postbariatric surgery are either
minimal or nonexistent and were therefore not discussed in
this paper.
5.1. Adiponectin. Adiponectin is a 244 aminoacid peptide.
It is the most abundant adipokine secreted by the adipose
tissue. Reduced levels of adiponectin are seen in obese
patients [102]. Adiponectin levels are signiﬁcantly lower as
well in diabetic patients and in those with cardiovascular
diseases compared to BMI-matched healthy controls [103,
104]. Studies in several adult populations have shown that
adiponectin predicts the development of T2D [105–107].
Adiponectin circulates as three oligomeric isoforms: low
molecular weight, medium molecular weight, and high
molecular weight isoforms. The HMW adiponectin repre-
sents the major active form mediating the favorable meta-
bolic eﬀects of adiponectin [108]. Adiponectin regulates in-
sulin sensitivity by increasing fatty acid oxidation, stimulat-
ing glucose uptake, and reducing hepatic gluconeogenesis
[109]. An increase in adiponectin levels is observed with
weight loss, and this increase is paralleled by an improved
insulin resistance [110].
After RYGB surgery, an increase in adiponectin levels has
been reported as shown in Table S3 [111–119].
5.2. Leptin. Leptin is a 167 aminoacid peptide secreted pri-
marily by the adipose tissue and circulates at levels propor-
tional to body fat. Leptin regulates appetite, energy expen-
diture, and body weight [120]. An increase in body fat is
associatedwithanincreaseinleptinlevelsthatacttodecrease
food intake. However, the elevated levels of leptin seen
in obese individuals do not eﬀectively suppress appetite
because of an underlying resistance to the hormone [121].
Theories for leptin resistance suggest a defect in blood brain
barrier transport of leptin induced by high-fat diets and
abnormalities in leptin receptor signaling [122–124]. The
eﬀects of leptin on glucose homeostasis are still unclear.
Leptin has been shown to enhance glucose uptake in skeletal
muscles, reduce hepatic glucose output, increase fatty acid
oxidation, and decrease insulin secretion by pancreatic beta
cells [125].
Serum leptin levels have been shown to be reduced after
RYGB surgery in several studies as presented in Table S4
[38, 57, 60, 110, 112, 115, 117, 126–130]. Whether bariatric
surgery results in an improvement in the leptin-resistant
state remains to be determined. However, the favorable
changes in leptin and adiponectin levels after RYGB surgery
are similarly seen with weight loss from other bariatric
surgery procedures [131]a sw e l la sf r o mp h a r m a c o l o g i c a l
[132] and dietary methods [133, 134] suggesting that these
changes are more related to fat loss rather than the RYGB
surgery itself.
6. Discussion
Studies evaluating hormonal changes after RYGB surgery
have shown an overall positive change in hormones, favoring8 ISRN Endocrinology
glycemic control. The orexigenic peptide ghrelin is reduced,
while the anorexigenic GLP-1, oxyntomodulin, and PYY are
increased.Hormonessuchasleptin,amylin,GIP,andinsulin,
to which a suggested state of resistance is observed in obesity
and T2D tend to decrease, favor a restored homeostasis.
Similarly, a change favoring improved insulin sensitivity
with increased adiponectin is seen (Figure 2). A summary
of the changes of all the peptides, along with their eﬀect on
glycemia and appetite is presented in Figure 3.
Despite the overall ﬁndings, there remain certain incon-
sistencies in the results which can be due to the following
factors: some studies lacked an appropriate control group
and merely assessed changes before and after RYGB surgery.
In the few prospective controlled studies, the follow-up time
did not exceed 2 years. As demonstrated in the Swedish
Obese Subjects Study (SOS), short-term observations (<2
years) cannot mirror the long-term eﬀects of bariatric
surgery on comorbidities [135].
Sampling time points varied from one study to another.
Some assessed fasting hormonal levels, whereas others mea-
sured the hormones in the postprandial state. Furthermore,
a standardized meal test is lacking and assays used to
measure the various hormones and peptides varied among
diﬀerent studies. For example, as previously mentioned
ghrelin exists in two forms: acyl ghrelin that has been shown
to produce stimulatory eﬀects on food intake and desacyl
ghrelin that induces a state of negative energy balance by
inhibiting food intake and delaying gastric emptying [21].
Measuring total, acyl, or desacyl ghrelin will potentially give
variable results. Therefore, this confounding factor must
be taken into consideration. In addition, other potential
explanations include the heterogeneity in the populations
studied, variability in the method of reporting weight loss,
and variability in the surgical techniques. Speciﬁc to changes
relating to ghrelin, levels can vary depending on diﬀerences
i nt h ep o u c hs i z ea sw e l la sc o n ﬁ g u r a t i o np a r t i c u l a r l y
if the pouch contains more fundic tissue. Variations in
technique are widely noted among diﬀerent surgeons. They
are also noted within the same surgeon’s experience as
diﬀerences in patient’s anatomy, body habitus, and eﬀect of
prior operations dictate modiﬁcations such as lengthening
or shortening the pouch [7, 136]. The stoma diameter is
important in determining how fast food is delivered to the
small intestine and may play a role in the hormonal changes
described above. Moreover, the length of the AL and BPL is
not standardized and might have an impact on one or more
of the gut incretins. Finally, one important factor not taken
into account in most studies is the lack of standardized use of
antidiabetic medications which can inﬂuence metabolites.
Even after consistent documentation of the hormonal
changes, an important question remains in establishing
the relationship of these alterations to metabolic control.
Is the overall favorable hormonal milieu a result of the
negative energy state or a causality of it? It may prove
diﬃcult to settle this point. However, controlled studies in
the immediate postoperative phase, within one day to one
week,wouldbehelpful.Exceptforonestudywhichmeasured
ghrelin levels as early as two hours postoperatively [34], the
vast majority obtain their ﬁrst measurement two to three
GLP-1 ↑
PYY ↑
OXM ↑
P
AL
BPL
GHRELIN ↓
GIP ↓
Figure 2: Changes in gut-related peptides post-RYGB surgery.
weeks postoperatively. Furthermore, comparison of changes
following very low-caloric diets similar in intake to the
immediate post-RYGB phase could prove interesting. These
are lacking and in practice may be diﬃcult to conduct.
7. Conclusion
In summary, in addition to the signiﬁcant and sustained
weight reduction achieved by RYGB surgery, improvement
in obesity comorbidities, insulin resistance, and glycemic
control is noted. This amelioration is attributed, at least
partly, to an alteration in gut peptide release and adipokines.
T h et i m i n ga n de x a c tc h a n g e so ft h e s eh o r m o n e s ,a sw e l la s
their etiologic link to metabolic control postsurgery need to
be better established.
Thus, long-term controlled studies and additional
research focusing on the very early phase post-RYGB are
required for a comprehensive appraisal of the mechanisms
behindT2Danditscontrol.Theseadvanceswillhelpidentify
new targets for pharmacological treatment of diabetes.
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Source Effect on appetite Effect on glycemia Levels post-RYGB
Ghrelin X/A-like cells stomach  increase  increase  decrease 
GIP K-cells/duodenum  no  effect increase  conﬂicting 
GLP-1 L-cells/distal  ileum  decrease  decrease  increase 
PYY L-cells/distal  ileum decrease  decrease  increase 
OXM L-cells/distal  ileum decrease  unclear 
Amylin beta cell/pancreas  decrease  decrease 
Insulin beta  cell/pancreas  decrease  decrease 
Leptin Adipose tissue  decrease unclear 
Adiponectin Adipose tissue  no effect  decrease  increase 
increase∗
decrease∗∗
decrease∗∗
decrease∗∗
Figure 3: Summary of changes in peptides after RYGB surgery and their eﬀects on glycemia and appetite. ∗Very few studies. ∗∗Hormonal
levels decrease but glycemia improves due to improved sensitivity.
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